Effects of Silymarin-Loaded Nanoparticles on HT-29 Human Colon Cancer Cells

Mombeini, Mohammad Amin; Saki, Ghasem; Khorsandi, Layasadat; Bavarsad, Neda

doi:10.3390/medicina54010001

Cited by 28 publications

(11 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, poor solubility and low bioavailability of QT have limited its therapeutic applications [15,16,17]. Several drug delivery systems, such as polymeric nanoparticles, solid lipid nanoparticles (SLNs), liposomes, and micelles, have examined to increase the bioavailability of anticancer agents [18,19,20,21].…”

Section: Introductionmentioning

confidence: 99%

Effects of Quercetin-Loaded Nanoparticles on MCF-7 Human Breast Cancer Cells

et al. 2019

Self Cite

View full text Add to dashboard Cite

: Background and objectives: Previous studies have shown anti-tumor activity of quercetin (QT). However, the low bioavailability of QT has restricted its use. This study aimed to assess the toxic effect of QT encapsulated in solid lipid nanoparticles (QT-SLNs) on the growth of MCF-7 human breast cancer cells. Materials and Methods: MCF-7 and MCF-10A (non-tumorigenic cell line) cell lines treated with 25 µmol/mL of QT or QT-SLNs for 48 h. Cell viability, colony formation, oxidative stress, and apoptosis were evaluated to determine the toxic effects of the QT-SLNs. Results: The QT-SLNs with appropriate characteristics (particle size of 85.5 nm, a zeta potential of −22.5 and encapsulation efficiency of 97.6%) were prepared. The QT-SLNs showed sustained QT release until 48 h. Cytotoxicity assessments indicated that QT-SLNs inhibited MCF-7 cells growth with a low IC50 (50% inhibitory concentration) value, compared to the free QT. QT-SLNs induced a significant decrease in the viability and proliferation of MCF-7 cells, compared to the free QT. QT-SLN significantly increased reactive oxygen species (ROS) level and MDA contents and significantly decreased antioxidant enzyme activity in the MCF-7 cells. Following QT-SLNs treatment, the expression of the Bcl-2 protein significantly decreased, whereas Bx expression showed a significant increase in comparison with free QT-treated cells. Furthermore, The QT-SLNs significantly increased apoptotic and necrotic indexes in MCF-7 cells. Viability, proliferation, oxidative stress and apoptosis of MCF-10A cells were not affected by QT or QT-SLNs. Conclusion: According to the results of this study, SLN significantly enhanced the toxic effect of QT against human breast cancer cells.

show abstract

Section: Introductionmentioning

confidence: 99%

Effects of Quercetin-Loaded Nanoparticles on MCF-7 Human Breast Cancer Cells

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Therefore, the encapsulation of silymarin into nanovehicles, such as liposomes, micelles, polymeric nanoparticles, or solid lipid nanoparticles could be a route to improving its solubility and bioavailability [ 115 – 119 ]. Generally speaking, both small hydrophilic and lipophilic molecules, or large proteins and nucleic acids can be delivered using liposomes [ 120 ]. Liposomes are vesicles enclosed by a spherical lipid bilayer, which have an aqueous core for carrying water soluble molecules, and a lipophilic membrane region for dissolving hydrophobic molecules.…”

Section: Silymarin and Gastrointestinal Cancermentioning

confidence: 99%

“…Nanosilymarin or free silymarin caused no significant alteration in the proliferation, viability, or apoptosis of NIH-3T3 normal control cells. Hence, nanosilymarin could be an improved formulation of silymarin to control colon cancer in humans [ 120 ]. Fig.…”

Section: Silymarin and Gastrointestinal Cancermentioning

confidence: 99%

Silymarin (milk thistle extract) as a therapeutic agent in gastrointestinal cancer

Fallah

Davoodvandi

Nikmanzar

et al. 2021

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

Silymarin contains a group of closely-related flavonolignan compounds including silibinin, and is extracted from Silybum marianum species, also called milk thistle. Silymarin has been shown to protect the liver in both experimental models and clinical studies. The chemopreventive activity of silymarin has shown some efficacy against cancer both in vitro and in vivo. Silymarin can modulate apoptosis in vitro and survival in vivo, by interfering with the expression of cell cycle regulators and apoptosis-associated proteins. In addition to its anti-metastatic activity, silymarin has also been reported to exhibit anti-inflammatory activity. The chemoprotective effects of silymarin and silibinin (its major constituent) suggest they could be applied to reduce the side effects and increase the anti-cancer effects of chemotherapy and radiotherapy in various cancer types, especially in gastrointestinal cancers. This review examines the recent studies and summarizes the mechanistic pathways and down-stream targets of silymarin in the therapy of gastrointestinal cancer.

show abstract

“…NP functionalization with target specific ligands, such as folic acid, aptamers, peptides, and antibodies, permits the targeted delivery of drugs. The culmination of these benefits is numerous drug delivery vehicles with reduced toxic side effects and improved pharmacokinetics, which vary according to surface physicochemical properties and size [30][31][32][33][34][35].…”

Section: Nanocarriersmentioning

confidence: 99%

Recent Trends in Nanocarrier-Based Targeted Chemotherapy: Selective Delivery of Anticancer Drugs for Effective Lung, Colon, Cervical, and Breast Cancer Treatment

Jin

Chen³

et al. 2020

Journal of Nanomaterials

View full text Add to dashboard Cite

Chemotherapy drugs are cytotoxic to tumor cells, but their lack of specificity leads to a range of side effects. The off-target effects of such drugs can be improved through the use of nanoparticles (NPs). Administered NPs show enhanced accumulation in tumor tissue near the blood vessels, enhancing both anticancer drug permeability and tumor retention. Several nanocarriers are now approved for clinical use in a range of cancer therapies, and many novel formulations are in the later stages of clinical trials. Here, we describe the advances in this area through the review of novel NP drug formulations developed over the last year. We focus specifically on lung, colon, cervical, and breast cancers and discuss the future of NPs as potential treatment options in these areas.

show abstract

Effects of Silymarin-Loaded Nanoparticles on HT-29 Human Colon Cancer Cells

Cited by 28 publications

References 34 publications

Effects of Quercetin-Loaded Nanoparticles on MCF-7 Human Breast Cancer Cells

Effects of Quercetin-Loaded Nanoparticles on MCF-7 Human Breast Cancer Cells

Silymarin (milk thistle extract) as a therapeutic agent in gastrointestinal cancer

Recent Trends in Nanocarrier-Based Targeted Chemotherapy: Selective Delivery of Anticancer Drugs for Effective Lung, Colon, Cervical, and Breast Cancer Treatment

Contact Info

Product

Resources

About